Yoshikazu Uenosono
Overview
Explore the profile of Yoshikazu Uenosono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
1983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hirano T, Shinsato Y, Tanabe K, Higa N, Kamil M, Kawahara K, et al.
Oncogenesis
. 2020 Feb;
9(2):13.
PMID: 32029704
Considering the poor prognosis of most advanced cancers, prevention of invasion and metastasis is essential for disease control. Ras homologous (Rho) guanine exchange factors (GEFs) and their signaling cascade could...
22.
Tanaka T, Arigami T, Uenosono Y, Yanagita S, Matsushita D, Okubo K, et al.
Surg Case Rep
. 2020 Jan;
6(1):13.
PMID: 31919764
Background: Patients with esophagogastric junction cancer are increasing in Western and Eastern countries. Conversely, the clinical significance of surgical resection remains controversial in these patients. We report a long-term survivor...
23.
Kijima T, Arigami T, Uenosono Y, Hiraki T, Yanagita S, Matsushita D, et al.
Anticancer Res
. 2020 Jan;
40(1):75-80.
PMID: 31892554
Background/aim: The aim of the present study was to compare human epidermal growth factor receptor 2 (HER2) expression before and after trastuzumab-based chemotherapy in patients with advanced HER2-positive gastric cancer....
24.
Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, et al.
BMC Cancer
. 2019 Jul;
19(1):672.
PMID: 31286873
Background: The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are representative blood markers of systemic inflammatory responses. However, the clinical significance of the combination of these markers is unclear. This...
25.
Fukuda K, Arigami T, Yanagita S, Matsushita D, Okubo K, Kijima T, et al.
Gan To Kagaku Ryoho
. 2019 Mar;
46(3):471-473.
PMID: 30914587
A 57-year-old woman was admitted to our hospital for treatment of gastric cancer presenting as a type 2 tumor in the lower third of the stomach. According to pre-therapeutic imaging...
26.
Kinami S, Takahashi M, Urushihara T, Ikeda M, Yoshida M, Uenosono Y, et al.
World J Clin Cases
. 2019 Jan;
6(16):1111-1120.
PMID: 30613669
Background: Postgastrectomy syndromes (PGS) after curative gastrectomy for gastric cancer are influenced by not only gastrectomy type but also by background factors. Recently, a nationwide PGS study was performed using...
27.
Ishigami S, Aridome K, Arigami T, Uenosono Y, Okumura H, Kita Y, et al.
Anticancer Res
. 2018 Oct;
38(10):5837-5841.
PMID: 30275208
Background/aim: We previously described the safety of distal jejunal pouch with Roux-en-Y reconstruction after total gastrectomy. The present prospective study evaluated its clinical benefit. Patients And Methods: Forty-five patients with...
28.
Arigami T, Uenosono Y, Yanagita S, Okubo K, Kijima T, Matsushita D, et al.
Ann Gastroenterol Surg
. 2018 Jun;
1(1):60-68.
PMID: 29863113
Circulating tumor cells (CTC) have been focused on as a target for detecting occult tumors, predicting therapeutic responses and prognoses, and monitoring postoperative recurrence in the clinical management of patients...
29.
Natsugoe S, Arigami T, Uenosono Y, Yanagita S
Ann Gastroenterol Surg
. 2018 Jun;
1(3):180-185.
PMID: 29863111
Recent prospective multicenter trials have demonstrated the clinical safety and efficacy of sentinel node navigation surgery (SNNS) in patients with early gastric cancer. Further, development of an intraoperative imaging system...
30.
Shimonosono M, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kijima Y, et al.
Oncotarget
. 2018 May;
9(31):22069-22078.
PMID: 29774123
Currently, immune checkpoint blockade against members of the B7/CD28 family is being used as a new molecular-targeted therapy, in patients with unresectable advanced or recurrent gastric cancer. Although human endogenous...